Don’t Consider Sotagliflozin a Diabetes Med
July 2023
New Rx sotagliflozin (Inpefa) will join dapagliflozin (Farxiga), empagliflozin (Jardiance), and other SGLT2 inhibitors.
But sotagliflozin is the only SGLT2 inhibitor NOT yet approved for treating type 2 diabetes.
It’s currently only approved to reduce the risk of heart failure urgent care visits and hospitalizations and cardiovascular death...in certain adults with OR without diabetes.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote